DMARD Use Does Not Increase COVID Hospitalization Save
An observational study of patients with systemic autoimmune inflammatory rheumatic diseases (AIRD) who also had COVID-19 disease shows that AIRD increased the risk of hospitalization, but that the use of disease-modifying antirheumatic drugs (DMARDs) were not associated with hospitalization.
An observational longitudinal cohort study conducted in March and April 2020 included 123 AIRD patients from a tertiary hospital in Madrid. Symptomatic COVID-19 were included and the main endpoints was hospital admission related to COVID-19.
Of the 123 AIRD patients, 54 patients were hospitalized with COVID-19. The mean age 69.7 years, and the median length of stay was 9 (6–14) days. Death occurred in 12 patients (22%).
Hospitalization was associated with older age (OR: 1.08; p=0.00) and autoimmune systemic condition (vs chronic inflammatory arthritis) (OR: 3.55; p=0.01), but not DMARD use.